Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Clinical trial NCT06391008 · UNKNOWN

Trial details

NCT number: NCT06391008
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer

Start date: 2024-04-30
Primary completion: 2024-12-30
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.